By Daniella Parra
Apollomics Inc. (Nasdaq: APLM) unveiled results from the KUNPENG clinical trial at ESMO 2023, showing vebreltinib’s potential as a treatment for cancers with MET alterations, they said.
The Phase 2 trial by Apollomics’ partner, Avistone Biotechnology Ltd., demonstrated a 75% overall response rate in patients with advanced NSCLC, along with other positive outcomes, the company said.
“The clinical results demonstrate the potential of vebreltinib as a new treatment for patients with cancers driven by MET alterations, particularly in Non-Small Cell Lung Cancer (NSCLC) with MetEx14 skipping mutation,” Guo-Liang Yu, Ph.D., co-founder, Chairman and Chief Executive Officer of Apollomics, said. “We are also pleased to see that vebreltinib is making progress in clinical programs for patients with various MET alterations.”
Editor@Executives-edge.com
